FirstWord

With $377 million in expected gross proceeds, Corxel plans to fund a Phase III trial of its oral weight-loss hopeful, CX11.

The regimen reduced the risk of radiographic progression of death by 52% in patients with HRR gene-mutated metastatic hormone-sensitive prostate cancer.

Popular LLMs favoured products that appeared prominently in Google searches or had dedicated Wikipedia pages.

Windward plans to use its IPO proceeds to advance TSLP-targeting antibodies designed to treat respiratory and skin diseases.

Patients on the B7-H3–targeting antibody-drug conjugate went a median of 5.5 months without progression or death, compared to 1.4 months on chemotherapy.

Hong Kong, Oct 27, 2026 - (ACN Newswire) - Micot Pharma (HKEX: 2335) presented its in-house neuroprotective drug candidate MT200605 in an oral presentation at the 18th World Stroke Congress (WSC 2026)...

In the backdrop of Europe's largest oncology event, FirstWord dives into Amgen's come-from-behind flex into oncology.

FirstWord will host an expert call with a KOL in the coming days to discuss the implications of Merck & Co. and Kelun-Biotech's Chinese Phase III OptiTROP-Lung06 study of frontline sac-TMT plus Keytruda in patients with PD-L1-negative non–small cell lung cancer.

Some might see dropping almost $1.3 billion on an early-stage asset with no published clinical data under its belt as a sizable gamble, particularly if the company making the bet has a track record of business development (BD) failures in its wake. But Gilead Sciences may be on to something this tim

TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolera...